New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations

Drug Development and Industrial Pharmacy

Volumn 37, Issue 7, 2011, Pages 775-789

  Mutlu, N Baaran ^a   Deǧim, Zelihagül ^a   Yilmaz, Şükran ^b   Eiz, Dinçç ^c   Nacar, Ahmet ^d  

^a GAZI UNIVERSITY   (Turkey)

^b Food and Mouth Diseases Institute   (Turkey)

^c KAFKAS UNIVERSITY   (Turkey)

^d MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

Alzheimer disease; liposome; MDCK; Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; BETA CYCLODEXTRIN DERIVATIVE; DIMETHYL BETA CYCLODEXTRIN; LIPOSOME; RIVASTIGMINE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DIALYSIS MEMBRANE; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; ENZYME ASSAY; ENZYME INHIBITION; HISTOPATHOLOGY; MALE; MONOLAYER CULTURE; MOUSE; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY;

ALZHEIMER DISEASE; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; BRAIN; CELL LINE; CHOLINESTERASE INHIBITORS; DOGS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NEUROPROTECTIVE AGENTS; PARTICLE SIZE; PHENYLCARBAMATES; TAUROCHOLIC ACID;

EID: 79958761285     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.541262     Document Type: Article

References (61)

1. Scarpini E, Scheltens P, Feldman H. (2003). Treatment of Alzheimerás disease: current status and new perspectives. Lancet Neurol, 2:539-547 (Pubitemid 36994993)
2. Polinsky RJ. (1998). Clinical pharmacology of rivastigmine: a newgeneration acetylcholinesterase inhibitor for the treatment of Alzheimerás disease. Clin Ther, 20:634-647 (Pubitemid 28421485)
3. Alloul K, Sauriol L, Kennedy W, Laurier C, Tessier G, Novosel S et al. (1998). Alzheimerás disease: a review of the disease, its epidemiology and economic impact. Arch Gerontol Geriatr, 27:189-221 (Pubitemid 28517904)
4. Delagarza VW. (2003). Pharmacologic treatment of Alzheimerás disesase: an update. Am Fam Phys, 68:1365-1372 (Pubitemid 37221614)
5. Smith MA, Perry G. (1998). What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease? J Chem Neuroanat, 16:35-41 (Pubitemid 29049097)
6. Standridge JB. (2004). Pharmacotherapeutic approaches to the treatment of Alzheimerás disease. Clin Ther, 26:615-630
7. Williams BR, Nazarians A, Gill MA. (2003). A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther, 25:1634-1653 (Pubitemid 36801939)
8. Farlow MR, Lilly ML; ENA713 B352 Study Group. (2005). Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimerás disease for up to 5 years. BMC Geriatr, 5:3
9. Agid Y, Dubois B, Anand R,Gharabawi G. (1998). Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res, 59:833-845
10. Yüksel N. (2000). Alzheimer hastaln ilala tedavisi. Klin Psikiyatr, 3:137-141
11. Ercan S. (2002). Alzheimer hastal tedavisinde kullanan kolinesteraz inhibitörleri. Demans, 2:5-9
12. Tse FL, Laplanche R. (1998). Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharm Res, 15:1614-1620 (Pubitemid 28465750)
13. Scherrman JM. (2002). Drug delivery to brain via the blood-brain barrier. Vasc Pharmacol, 38:349-354
14. Pardridge WM. (2007). Blood-brain barrier delivery. Drug Discov Today, 12:54-61 (Pubitemid 46014479)
15. Jeffrey P, Summerfield SG. (2007). Challenges for blood-brain barrier (BBB) screening. Xenobiotica, 37:1135-1151 (Pubitemid 350041554)
16. Gumbleton M, Audus KL. (2001). Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci, 90:1681-1698 (Pubitemid 33062590)
17. Hawkins RA, OáKane RL, Simpson IA, Viña JR. (2006). Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr, 136:218S-226S
18. Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP. (2002). Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm Res, 19:976-981 (Pubitemid 34804239)
19. Braun A, Hämmerle S, Suda K, Rothen-Rutishauser B, Günthert M, Krämer SD et al. (2000). Cell cultures as tools in biopharmacy. Eur J Pharm Sci, 11 Suppl 2:S51-S60
20. Wilson G. (1990). Cell culture techniques for the study of drug transport. Eur J Drug Metab Pharmacokinet, 15:159-163 (Pubitemid 20219063)
21. Lemaire M, Desrayaund S. (2005). The priorities/needs of the pharmaceutical industry in drug delivery to the brain. Int Cong Ser, 1277:32-46 (Pubitemid 43693338)
22. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD et al. (2005). In vitro models for the blood-brain barrier. Toxicol in Vitro, 19:299-334 (Pubitemid 40248750)
23. Degim Z, Mutlu NB, Yilmaz S, Essiz D, Nacar A. (2010). Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie, 65:32-40
24. Shah P, Jogani V, Mishra P, Mishra AK, Bagchi T, Misra A. (2008). In vitro assessment of acyclovir permeation across cell monolayers in the presence of absorption enhancers. Drug Dev Ind Pharm, 34:279-288 (Pubitemid 351431202)
25. Wen H, Watry DD, Marcondes MC, Fox HS. (2004). Selective decrease in paracellular conductance of tight junctions: role of the first extracellular domain of claudin-5. Mol Cell Biol, 24:8408-8417 (Pubitemid 39245063)
26. Shi LZ, Zheng W. (2005). Establishment of an in vitro brain barrier epithelial transport system for pharmacological and toxicological study. Brain Res, 1057:37-48 (Pubitemid 41338085)
27. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. (2005). Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. Neurorx, 2:554-571 (Pubitemid 41393265)
28. Micklus MJ, Greig NH, Tung J, Rapoport SI. (1993). Targetting of liposomes to the blood-brain barrier in rats. Drug Deliv, 1:21-26
29. Uhumwango MU, Okor RS. (2005). Current trends in the production and biomedical applications of liposomes: a review. J Med Biomed Res, 4:9-21
30. Lasic DD. (1998). Novel applications of liposomes. Trends Biotechnol, 16:307-321 (Pubitemid 28305254)
31. Degim Z. (2008). Use of microparticulate systems to accelerate skin wound healing. J Drug Target, 16:437-448 (Pubitemid 352015812)
32. Alemdaroglu C, Degim Z, Celebi N, Sengezer M, Alömeroglu M, Nacar A. (2008). Investigation of epidermal growth factor containing liposome formulation effects on burn wound healing. J Biomed Mater Res A, 85:271-283 (Pubitemid 351355377)
33. Degim Z, Unal N, Essiz D, Abbasoglu U. (2004). The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci, 75:2819-2827 (Pubitemid 39349268)
34. Allen TM. (1997). Liposomes. Opportunities in drug delivery. Drugs, 54 Suppl 4:8-14 (Pubitemid 27487790)
35. Rao BM, Srinivasu MK, Kumar KP, Bhradwaj N, Ravi R, Mohakhud PK et al. (2005). A stability indicating LC method for rivastigmine hydrogen tartrate. J Pharm Biomed Anal, 37:57-63 (Pubitemid 40138716)
36. El-Gazayerly ON, Hikal AH. (1997). Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int J Pharm, 158:121-127 (Pubitemid 28012898)
37. Li H, Song JH, Park JS, Han K. (2003). Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm, 258:11-19 (Pubitemid 36712866)
38. Cong W, Liu Q, Chen X, Gao R, Lu J, Wang Y et al. (2010). Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev Ind Pharm, 36:1186-1194
39. Yeh YH, Hwang DF. (2001). High-performance liquid chromatographic determination for bile components in fish, chicken and duck. J Chromatogr B Biomed Sci Appl, 751:1-8
40. Basappa C, Rao P, Rao DN, Divakar S. (1998). A modified colorimetric method for the estimation of -cyclodextrin using phenolphthalein. Int J Food Sci Tech, 33:517-520 (Pubitemid 128384857)
41. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65:55-63 (Pubitemid 14203433)
42. Raiman J, Törmälehto S, Yritys K, Junginger HE, Mönkkönen J. (2003). Effects of various absorption enhancers on transport of clodronate through Caco-2 cells. Int J Pharm, 261:129-136 (Pubitemid 36962751)
43. Zerrouk N, Corti G, Ancillotti S, Maestrelli F, Cirri M, Mura P. (2006). Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability. Eur J Pharm Biopharm, 62:241-246 (Pubitemid 43356571)
44. Meaney CM, OáDriscoll CM. (2000). A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt:fatty acid micellar systems using the CaCo-2 cell culture model. Int J Pharm, 207:21-30
45. Duplay D. (2004). Physiciansá Desk Reference, 58th edn. Montvale: Thomson PDR, pp. 2252-2260
46. Enz A, Gentsch C. (2004). Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology, 47:408-413 (Pubitemid 38953232)
47. Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, Sachak S. (2005). Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res, 1033:186-193 (Pubitemid 40193413)
48. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 7:88-95
49. Begley DJ, Bradbury MW, Kreuter J. (2000). The blood-brain barrier and drug delivery to the CNS. New York: Marcel Dekker
50. Fagerholm U. (2007). The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discov Today, 12:1076-1082 (Pubitemid 350186133)
51. Sakamoto A, Ido T. (1993). Liposome targeting to rat brain: effect of osmotic opening of the blood-brain barrier. Brain Res, 629:171-175 (Pubitemid 23328804)
52. Visser CC, Stevanovic S, Voorwinden LH, van Bloois L, Gaillard PJ, Danhof M et al. (2005). Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur J Pharm Sci, 25:299-305 (Pubitemid 40725060)
53. Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. (2008). A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm, 58:287-297
54. Mura P, Maestrelli F, González-Rodrãguez ML, Michelacci I, Ghelardini C, Rabasco AM. (2007). Development, characterization and in vivo evaluation of benzocaine-loaded liposomes. Eur J Pharm Biopharm, 67:86-95 (Pubitemid 46991345)
55. Potts RO, Guy RH. (1992). Predicting skin permeability. Pharm Res, 9:663-669
56. Higuchi T. (1960). Physical chemical analysis of percutaneous absorption from creams and ointments. J Soc Cosmet Chem, 11:85-97
57. Freshney RI. (1994). Culture of Animal Cells, 4th edn. Canada: Wiley-Liss, Inc
58. Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J et al. (2005). Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm, 288:349-359 (Pubitemid 40038588)
59. Kusuhara H, Sugiyama Y. (2005). Efflux transport systems at bloodbrain barrier and blood CFS barrier, Int Cong Ser, 1277:111-122 (Pubitemid 43693339)
60. Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, de Sousa A, Borchard G et al. (2006). Uptake studies in rat Peyerás patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release, 114:348-358 (Pubitemid 44310817)
61. Degim IT, Gümüsel B, Degim Z, Ozelikay T, Tay A, Güner S. (2006). Oral administration of liposomal insulin. J Nanosci Nanotechnol, 6:2945-2949 (Pubitemid 44579966)